177 related articles for article (PubMed ID: 36072540)
21. Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring.
Hassan A; Burhenne J; Riedel KD; Weiss J; Mikus G; Haefeli WE; Czock D
Ther Drug Monit; 2011 Feb; 33(1):86-93. PubMed ID: 21192313
[TBL] [Abstract][Full Text] [Related]
22. Voriconazole pharmacokinetics and exposure-response relationships: assessing the links between exposure, efficacy and toxicity.
Dolton MJ; McLachlan AJ
Int J Antimicrob Agents; 2014 Sep; 44(3):183-93. PubMed ID: 25106074
[TBL] [Abstract][Full Text] [Related]
23. Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.
Iwamoto T; Monma F; Fujieda A; Nakatani K; Katayama N; Okuda M
Clin Ther; 2011 Aug; 33(8):1077-80. PubMed ID: 21802143
[TBL] [Abstract][Full Text] [Related]
24. Recent Advances in Therapeutic Drug Monitoring of Voriconazole, Mycophenolic Acid, and Vancomycin: A Literature Review of Pediatric Studies.
Resztak M; Sobiak J; Czyrski A
Pharmaceutics; 2021 Nov; 13(12):. PubMed ID: 34959272
[TBL] [Abstract][Full Text] [Related]
25. CYP2C19 is involved in the effect of Wuzhi tablet (
Yuan F; Liang X; Chen X; Qin X; Tan C; Wang L
Pharmazie; 2020 Nov; 75(11):559-564. PubMed ID: 33239129
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients--an evidence-based approach.
Karthaus M; Lehrnbecher T; Lipp HP; Kluge S; Buchheidt D
Ann Hematol; 2015 Apr; 94(4):547-56. PubMed ID: 25697592
[TBL] [Abstract][Full Text] [Related]
27. Effects of the CYP2C19 genetic polymorphism on gastritis, peptic ulcer disease, peptic ulcer bleeding and gastric cancer.
Jainan W; Vilaichone RK
Asian Pac J Cancer Prev; 2014; 15(24):10957-60. PubMed ID: 25605208
[TBL] [Abstract][Full Text] [Related]
28. CYP2C19 Phenotype and Body Weight-Guided Voriconazole Initial Dose in Infants and Children after Hematopoietic Cell Transplantation.
Takahashi T; Mohamud MA; Smith AR; Jacobson PA; Jaber MM; Alharbi AF; Fisher J; Kirstein MN
Antimicrob Agents Chemother; 2021 Aug; 65(9):e0062321. PubMed ID: 34097481
[TBL] [Abstract][Full Text] [Related]
29. Voriconazole plasma concentrations and dosing in paediatric patients below 24 months of age.
Gastine SE; Rauwolf KK; Pieper S; Hempel G; Lehrnbecher T; Tragiannidis A; Groll AH
Mycoses; 2023 Nov; 66(11):969-976. PubMed ID: 37553971
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.
Moriyama B; Kadri S; Henning SA; Danner RL; Walsh TJ; Penzak SR
Curr Fungal Infect Rep; 2015 Jun; 9(2):74-87. PubMed ID: 26918067
[TBL] [Abstract][Full Text] [Related]
31. Impact of CYP2C19 gene polymorphism on warfarin maintenance doses in patients with non-valvular atrial fibrillation.
Zhang H; Ma K; Liu W; Yang F; Liu J; Zhou H
Gene; 2016 Oct; 591(1):80-84. PubMed ID: 27356304
[TBL] [Abstract][Full Text] [Related]
32. Prospective CYP2C19-Guided Voriconazole Prophylaxis in Patients With Neutropenic Acute Myeloid Leukemia Reduces the Incidence of Subtherapeutic Antifungal Plasma Concentrations.
Hicks JK; Quilitz RE; Komrokji RS; Kubal TE; Lancet JE; Pasikhova Y; Qin D; So W; Caceres G; Kelly K; Salchert YS; Shahbazian K; Abbas-Aghababazadeh F; Fridley BL; Velez AP; McLeod HL; Greene JN
Clin Pharmacol Ther; 2020 Mar; 107(3):563-570. PubMed ID: 31549389
[TBL] [Abstract][Full Text] [Related]
33. Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis.
Li X; Yu C; Wang T; Chen K; Zhai S; Tang H
Eur J Clin Pharmacol; 2016 Oct; 72(10):1185-1193. PubMed ID: 27388292
[TBL] [Abstract][Full Text] [Related]
34. Longitudinal Analysis of the Effect of Inflammation on Voriconazole Trough Concentrations.
Encalada Ventura MA; van Wanrooy MJ; Span LF; Rodgers MG; van den Heuvel ER; Uges DR; van der Werf TS; Kosterink JG; Alffenaar JW
Antimicrob Agents Chemother; 2016 May; 60(5):2727-31. PubMed ID: 26883707
[TBL] [Abstract][Full Text] [Related]
35. The Influence of Proinflammatory Cytokines on Voriconazole Trough Concentration in Patients With Different Forms of Hematologic Disorders.
Mafuru M; Wu S; He S; Lu X; Huang J; Jiang H
J Clin Pharmacol; 2019 Oct; 59(10):1340-1350. PubMed ID: 30997931
[TBL] [Abstract][Full Text] [Related]
36. Impact of CYP2C19 Phenotype and Drug-Drug Interactions on Voriconazole Concentration in Pediatric Patients.
Tian X; Zhang C; Qin Z; Wang D; Yang J; Zhang X
Antimicrob Agents Chemother; 2021 Aug; 65(9):e0020721. PubMed ID: 34152823
[TBL] [Abstract][Full Text] [Related]
37. A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug Interactions.
Li X; Frechen S; Moj D; Lehr T; Taubert M; Hsin CH; Mikus G; Neuvonen PJ; Olkkola KT; Saari TI; Fuhr U
Clin Pharmacokinet; 2020 Jun; 59(6):781-808. PubMed ID: 31853755
[TBL] [Abstract][Full Text] [Related]
38. Influence of CYP2C19*2/*17 genotype on adverse drug reactions of voriconazole in patients after allo-HSCT: a four-case report.
Beata S; Donata UK; Jarosław D; Tomasz W; Anna WH
J Cancer Res Clin Oncol; 2017 Jun; 143(6):1103-1106. PubMed ID: 28247033
[TBL] [Abstract][Full Text] [Related]
39. The Diagnostic Utility of the Point-of-Care CYP2C19 Genotyping Assay in Patients with Acute Coronary Syndrome Dosing Clopidogrel: Comparison with Platelet Function Test and SNP Genotyping.
Choi JL; Kim BR; Woo KS; Kim KH; Kim JM; Kim MH; Han JY
Ann Clin Lab Sci; 2016 Sep; 46(5):489-94. PubMed ID: 27650615
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
